title: Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomes.
abstract: Cancer registries have proven valuable with respect to validating therapeutic safety and drug efficacy, uncovering real-world implementation practices, and their evolution over time. Modern cancer therapeutics are approved as single agents oftentimes compared to the least active approved standard agent in randomized trials. However, the burgeoning diversity and number of drugs introduces a complexity that quickly outstrips the knowledge provided by these pivotal trials. This gap in information is particularly relevant when survival is the primary therapeutic endpoint. In addition, the inherent complexity of the immune response will make registries a particularly important tool in expeditiously understanding solid tumor immunotherapy and patient outcomes.
authors.affiliation: Department of Medicine, Suite 3455, University of Southern California, 1441 Eastlake Avenue, Los Angeles, CA 90033, USA.
authors.forename: Michael K
authors.initials: MK
authors.lastname: Wong
authors.affiliation: Department of Surgery, Room 2007, Rutgers Cancer Center Institute of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08901, USA.
authors.forename: Howard L
authors.initials: HL
authors.lastname: Kaufman
authors.affiliation: Moores Cancer Center, University of California San Diego, 3855 Health Sciences Drive, La Jolla, CA 92093, USA.
authors.forename: Gregory A
authors.initials: GA
authors.lastname: Daniels
authors.affiliation: Beth Israel Hospital Deaconess Medical Center, Masco Building, 375 Longwood Avenue, Boston, MA 02215, USA.
authors.forename: David F
authors.initials: DF
authors.lastname: McDermott
authors.affiliation: Prometheus Laboratories Inc., 9410 Carroll Park Drive, San Diego, CA 92121, USA.
authors.forename: Sandra
authors.initials: S
authors.lastname: Aung
authors.affiliation: Prometheus Laboratories Inc., 9410 Carroll Park Drive, San Diego, CA 92121, USA.
authors.forename: James N
authors.initials: JN
authors.lastname: Lowder
authors.affiliation: Duke University Medical Center, Mudd Building, Rm 437, 10 Bryan Searle Drive, Durham, NC 27710, USA.
authors.forename: Michael A
authors.initials: MA
authors.lastname: Morse
keywords: Cancer; Cure; Immunotherapy; Interleukin-2; Melanoma; Metastatic; Registry; Renal cell carcinoma